Trial Profile
Ferric Carboxymaltose (Ferinject®) Administered After Cardiac Surgery: (FCAACS) Effects On Correction Of Anemia And Transfusion Rates: A Prospective Randomized Controlled Trial
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2021
Price :
$35
*
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms FCAACS
- 08 Oct 2021 Status changed from recruiting to completed.
- 06 Dec 2018 New trial record